Daewoong Pharmaceutical and Daewoong Therapeutics have made a groundbreaking advancement in drug delivery technology with their semaglutide microneedle patch, boasting over 80% relative bioavailability compared to injectable formulations in a recent pilot study. This achievement, made possible by the CLOPAM® drug-delivery platform, marks a significant leap forward in enhancing delivery efficiency for high-dose biologics.
The pilot study, which involved 70 healthy adults comparing the microneedle patch to subcutaneous injection, demonstrated exceptional bioavailability, surpassing existing microneedle patches by a wide margin and providing a bioavailability level approximately 160 times higher than the semaglutide oral tablet. The sustained therapeutic plasma levels achieved for a week support the potential for a once-weekly dosing regimen, offering a convenient and effective treatment option for patients.
The global obesity therapeutics market, valued at $15.9 billion in 2024 and projected to reach $60.5 billion by 2030, presents a significant opportunity for innovative drug delivery technologies. Microneedle patches, such as Daewoong’s semaglutide patch, address key limitations of current therapies by offering a needle-free, high-bioavailability alternative that enhances patient convenience and adherence. The technology’s ability to maintain stability at room temperature also aligns with sustainability goals in healthcare by reducing distribution costs and medical waste.
Daewoong Therapeutics’ patented CLOPAM® microneedle platform technology has positioned the company as a leader in the field, with 52 patent filings worldwide. The platform’s unique design, utilizing pressurized drying and hermetic packaging, ensures precise drug delivery with minimal contamination risk. This breakthrough not only overcomes previous challenges in high-dose microneedle delivery but also paves the way for expanding the technology to a range of biologics, positioning Daewoong at the forefront of the global drug delivery market.
Looking ahead, Daewoong Therapeutics plans to leverage its success with the microneedle patch through global initiatives such as technology licensing and co-development, laying the groundwork for commercialization on a broader scale. By demonstrating the potential for high bioavailability and therapeutic efficacy in a once-weekly application, the company is poised to revolutionize drug delivery practices and establish itself as a key player in the evolving landscape of biologic therapeutics.
Key Takeaways:
1. Daewoong’s semaglutide microneedle patch showcases over 80% relative bioavailability compared to injectable formulations, offering a high-dose, once-weekly treatment option for patients.
2. The global obesity therapeutics market presents a lucrative opportunity for innovative drug delivery technologies that enhance patient convenience and adherence.
3. Daewoong’s patented CLOPAM® microneedle platform technology positions the company as a leader in precise, high-bioavailability drug delivery, with potential applications across a range of biologics.
4. By expanding global initiatives and commercialization efforts, Daewoong Therapeutics aims to revolutionize drug delivery practices and establish itself as a frontrunner in the biologic therapeutics market.
Tags: formulation, drug delivery
Read more on koreaherald.com